Skip to main content
. 2016 May 31;7(27):42195–42207. doi: 10.18632/oncotarget.9743

Figure 3. CXCL2 contributes to the synergistic anti-tumor effects of HVJ-E+poly I:C.

Figure 3

A. Expression of CXCL1 and 2 in the TME of B16-F10 melanoma in mice was assessed by qPCR (n=6). The effects of anti-CXCL1 (5 μg/mouse) B. or CXCL2 (50 μg/mouse) C. antibodies on tumor suppression with HVJ-E+poly I:C (H+P) (25 μg+2500 HAU) treatment were analyzed in melanoma-bearing mice (n=6). As a negative control, an isogenic antibody (Iso) was used. Antibodies were intratumorally administered three times 24 hours before HVJ-E+poly I:C injection and once 24 hours after the treatment (a total of four times). The tumor weight was compared between each treatment. * Indicates p<0.05.